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The X-ray crystal structure of sangivamycin, a potent nucleoside inhibitor of protein kinases, has been determined. Sangivamycin crystallizes from 
water with its purine ring in a conformation anti to its ribose sugar. Such an anti conformation has been detected in solution for sangivamycin 
and other potent protein kinase inhibitors and appears to correlate with inhibitor potency [(1990) Biochemistry (in press)]. An intramolecular hydro- 
gen bond between purine ring substituents is detected in the X-ray structure and may be an important structural feature of sangivamycin related 
to its degree of inhibition of rhodopsin kinase and of protein kinases C and A. 
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1. INTRODUCTION 
Inhibitors are very useful tools for studying the role 
and function of enzymes. In order to design the most 
potent and specific inhibitors, information about in- 
hibitor structure is necessary. Such structural informa- 
tion should Serve as a guide for development of even 
more potent and selective inhibitors. 
Protein kinases catalyze phosphotransfer reactions 
from an ATP/GTP donor to a protein substrate. These 
enzymes are involved in most cellular, metabolic, 
transduction and proliferation processes. 
Inhibitors of protein kinases can be divided into two 
classes: those that compete with the protein substrate 
(either as an integral part of the enzyme, or in- 
dependently, (e.g. see [2-4]); and those that compete at 
the ATP/GTP binding site [5-10]. 
Sangivamycin inhibits protein kinases, including 
nuclear protein kinases [11], protein kinases A and C 
[12], and rhodopsin kinase [I]. This naturally occurring 
antibiotic (synthesized by Streptomyces rimosus) also 
has significant antitumor activity against L 1210 
leukemia in mice [13]. 
Sangivamycin assumes predominantly the anti con- 
formation (sugar anti to the base) in solution as deter- 
mined by Nuclear Overhauser Effect measurements. 
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This anti conformation appears to be required for effi- 
cient nucleoside binding to rhodopsin kinase [1] and 
presumably to other protein kinases. In this report we 
present the solid state structure of sangivamycin. 
2. MATERIALS AND METHODS 
Sangivamycin was obtained from the National Institutes of Health, 
National Cancer Institute (Natural Products Branch) Division of 
Cancer Treatment. 
Crystals of sangivamycin monohydrate were grown from aqueous 
solution by slow evaporation i the open atmosphere. Crystal data: 
C1zHIsNsOs'H20, Mr=328.1, orthorhombic, a=11.694 (3) ,~, 
b = 17.519 (4) A, V= 1388 ,~3, Z= 4, D¢~c = 1.571 g. cm -3,/z (Mo K~ 
radiation)=l.19 cm -1. Space group P212~2~ from systematic 
absences. Crystal dimensions 0.2 x 0.1 × 0.1 mm. 
Intensity data to 0=23 ° were collected with an Enraf-Nonius 
CAD-4 diffractometer using w/26 scans. A total of 1164 reflections 
were recorded and the usual Lorentz and polarization corrections 
were applied [14]. The unit cell parameters were calculated from the 
diffractometer setting angles for 25 general reflections. 
The crystal structure was solved by direct methods using the 
SHELXS-86 program [14]. Approximate coordinates for the non- 
hydrogen atoms of the aromatic rings were obtained from an E-map. 
The rest of the molecule was found in subsequent difference Fourier 
maps. A total of 698 reflections, which had Fo > 4a(Fo), were used in 
the structure refinement. Hydrogen atoms, whose positions could be 
calculated from the positions of heavy-atoms, were not refined. The 
hydrogen atoms of the hydroxyl groups and the water molecule were 
located in difference Fourier maps and their positions were refined 
with the oxygen-hydrogen distance restrained to 1.08 ,~. The refine- 
ment converged at R=0.045 and Rw=0.042 where R=,~llFo [ - 
[Ecll/2?lFol and R,=~/Ew(IFo I - IE¢l)2/SwlFo[ 2 while w -1= 
(a2(F)+0.0004 F2). The refinement was carried out using the 
SHELX-76 program. The values of interatomic distances, bond 
angles, and torsion angles are available from the authors. 
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Fig. 1. Solid-state conformation of sangivamycin in crystals of 
monohydrate. C, O and N are labeled, H atoms are represented by 
small circles. A hydrogen bond is marked with a broken line. 
to the base, a conformation which has been detected in 
solution [1]. The fractional coordinates and estimated 
standard eviations are presented in Table I. 
The furanoside ring has an envelope conformation 
with C(3') displaced by 0.48 A from the least squares 
plane through the other four ring atoms. The plane is 
almost perpendicular (85 °) to the best plane through the 
aromatic rings. Steric hindrance between the amido 
group (N10) on C6 and the amino group (Cl l ,  O12, 
N13) on C7 is alleviated by a 30 ° rotation of the amide 
group from the purine plane. One of the hydrogen 
atoms of the amino group forms an intramolecular H- 
bond with the oxygen of the amide moiety. 
A stereo view of the packing arrangement of crystal- 
lized sangivamycin s presented in Fig. 2. The condens- 
ed rings are stacked along the c-axis (Fig. 2) with the 
5-membered ring sandwiched between the 6-membered 
ring and vice versa. The shortest interplanar inter- 
atomic distance, at 3.30 [1] A occurs between C(4) and 
C(6). 
Sangivamycin and water molecules are associated by 
an extensive network of hydrogen bonds involving the 
two amino and 3 hydroxy groups and both water 
molecules (Table II). 
3. RESULTS 
The molecular structure of sangivamycin s shown in 
Fig. 1. The most significant finding is that the fura- 
noside ring assumes an anti conformation with respect 
Fractional 
Table I
atomic coordinates with e.s.d.s, in parentheses and 
equivalent isotropic temperature factors 
X/a Y/b Z/c B (A 2) 
N(1) 
C(2) 
N(3) 
C(4) 
c(5) 
C(6) 
C(7) 
c(8) 
N(9) 
N(10) 
C(l l) 
O(12) 
N(13) 
C(1 ') 
C(2' ) 
C(3') 
C(4') 
c(5') 
O(6') 
0(7') 
0(8') 
O(9') 
ow 
0.8935(6) -0.0003(4) 0.0456(11) 2.70 
0.8706(7) 0.0746(4) 0.0537(15) 2.30 
0.7706(5) 0.1094(3) 0.0520(12) 2.32 
0.6839(7) 0.0602(4) 0.0513(14) 1.97 
0.6923(7) - 0.0204(4) 0.0454(14) 2.05 
0.8051(8) -0.0490(4) 0.0372(14) 2.23 
0.5774(7) -0.0489(5) 0.0600(15) 2.20 
0.5061(6) 0.0135(4) 0.0596(13) 2.21 
0.5697(5) 0.0796(3) 0.0508(11) 2.13 
0.8274(6) -0.1244(4) 0.0260(12) 2.94 
0.5399(9) - O. 1284(5) 0.0809(16) 2.99 
0.5968(6) -0.1815(3) 0.0072(9) 3.90 
0.4420(7) -0.1399(4) 0.1751(13) 3.49 
0.5231(7) 0.1566(4) 0.0538(16) 2.72 
0.4531(7) 0.1772(5) - O. 1280(14) 2.41 
0.3309(6) 0.1773(4) -0.0550(14) 1.83 
0.3436(6) O. 1967(5) O. 1655(14) 2.34 
0.2515(7) 0.1669(5) 0.2997(15) 3.30 
0.4518(5) 0.1630(3) 0.2197(9) 2.96 
0.4887(5) 0.2521(3) -0.1836(10) 4.42 
0.2555(5) 0.2275(3) -0.1557(9) 2.61 
0.2348(5) 0.0861(3) 0.2768(9) 3.12 
0.1297(5) 0.0090(4) 0.9804(11) 4.72 
4. DISCUSSION 
Sangivamycin s the most potent inhibitor of rhodop- 
sin kinase and one of the most effective blockers of pro- 
tein kinase C [1,12]. In solution, sangivamycin assumes 
predominantly the anti conformation, as determined by 
Nuclear Overhauser measurements. This conforma- 
tional property is shared by other kinase nucleoside in- 
hibitors and is lacking in compounds that are poor in- 
hibitors, and therefore may be related to its inhibitory 
properties [1]. 
In the solid state, sangivamycin also exists in the anti 
conformation. Moreover, our studies reveal that the 
N(10) amine is involved in an intramolecular hydrogen 
bond with the carbonyl residue of the amide group at 
C(7), a bond planar with the base. This feature of the 
intermolecular hydrogen bond may help explain why 
the C10 amide yields a more potent inhibitor for 
rhodopsin kinase than the C10 nitrile, amidine or 
amidoxime [1] and suggests a structure to mimic in the 
search for even more potent inhibitors. The amide 
group at C(7) also may interact via hydrogen bond with 
an enzyme. In addition, the conformation of the 
ribofuranoside can play an important role in protein- 
nucleoside recognition. Newman projection reveals that 
sangivamycin assumes trans-gauche conformation 
about the backbone C(5') -O(5')  bond and gauche- 
gauche staggered conformation about the exocyclic 
C(4' ) -C(5' )  bond, as suggested for nucleosides with 
anti sugar-base torsion preferred in the anti position 
[15]. 
103 
Volume 266, number 1,2 FEBS LETTERS June 1990 
) 
,q 
I 
I 
'-t 
Fig. 2. Stereoview of the packing of sangivamycin molecules in the crystals seen approximately along the c-axis. 
Table II 
Hydrogen-bonded distances for sangivamycin monohydrate 
D-H...A D-A (#,) H...A (A) 
N(10)-H(4)....O(12) 2.88(1) 1.90 
N(13)-H(5)....O(8') I 3.00(1) 2.12 
N( 13 )- H(6).... O(W) u 3.20( 1 ) 2.12 
O(7')-H(7')....O(12) m 2.68(1) 1.74 
O(8')-H(8')....N(3) TM 2.95(1) 1.91 
0(9' )-H(9' )....O(W) n 2.68( 1 ) 1.62 
O(W)-H(IW)....O(9') v 2.71(1) 1.72 
O(W)-H (2W)....N( 1 )v 2.80( 1 ) 1.80 
Roman numeral superscripts 
equivalent positions: 
i 0.5-x, -y ,  -0 .5+z  
II 0.5-X, - -y ,  0.5 + Z 
m l-x, - 0.5 +y, -0.5-Z 
iv 0.5 +x, 0.5-y, -Z 
V x, y, -1 +z 
refer to atoms in the following 
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